scholarly article | Q13442814 |
P356 | DOI | 10.1016/S0140-6736(89)91016-7 |
P698 | PubMed publication ID | 2572740 |
P50 | author | Michael Houghton | Q1927895 |
P2093 | author name string | M Colombo | |
G Kuo | |||
Q L Choo | |||
E Del Ninno | |||
M F Donato | |||
N Dioguardi | |||
M A Tommasini | |||
P2860 | cites work | Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome | Q27860719 |
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis | Q27860909 | ||
NIH conference. Hepatocellular carcinoma | Q38184652 | ||
Non-A, non-B hepatitis: evolving epidemiologic and clinical perspective. | Q39502500 | ||
Cirrhosis and the aetiology of hepatocellular carcinoma | Q39508676 | ||
Relationship between hepatocellular carcinoma and cirrhosis | Q40077062 | ||
Risk factors for hepatocellular carcinoma in Italy. Male sex, hepatitis B virus, non-A non-B infection, and alcohol | Q45841358 | ||
Hepatitis C virus antibodies among risk groups in Spain | Q45844599 | ||
Risk factors for hepatocellular carcinoma in Northern Italy | Q57562717 | ||
Viral superinfection | Q69722780 | ||
A multicenter, prospective study of posttransfusion hepatitis in Milan | Q70349298 | ||
Primary hepatocellular carcinoma after chronic non-A, non-B post-transfusion hepatitis | Q72400334 | ||
Primary hepatocellular carcinoma following non-A, non-B posttransfusion hepatitis | Q72711744 | ||
P433 | issue | 8670 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Italy | Q38 |
antibody | Q79460 | ||
hepatitis C | Q154869 | ||
patient | Q181600 | ||
Hepatitis C virus | Q708693 | ||
P304 | page(s) | 1006-1008 | |
P577 | publication date | 1989-10-01 | |
P1433 | published in | The Lancet | Q939416 |
P1476 | title | Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma | |
P478 | volume | 2 |
Q53347425 | A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. |
Q45210037 | A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis |
Q42988527 | A randomized controlled trial of interferon-alpha in patients with cirrhosis caused by 2a/2b genotype hepatitis C virus |
Q39385948 | A retrospective study of hepatitis C virus carriers in a local endemic town in Japan. A possible presence of asymptomatic carrier |
Q42632605 | A structural protein encoded by the 5' region of the hepatitis C virus genome efficiently detects viral infection |
Q42985662 | A structural protein of hepatitis C virus expressed in E. coli facilitates accurate detection of hepatitis C virus |
Q45770049 | Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. |
Q91729031 | Ages of hepatocellular carcinoma occurrence and life expectancy are associated with a UGT2B28 genomic variation |
Q53460729 | Alcohol, hepatotropic viruses, and hepatocellular carcinoma. |
Q50994209 | Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. |
Q36033548 | Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development |
Q42981000 | Alteration of DNA ploidy and cell nuclearity in human hepatocellular carcinoma associated with HBV infection |
Q39813695 | An Assessment of the Use of Chimpanzees in Hepatitis C Research Past, Present and Future: 1. Validity of the Chimpanzee Model |
Q41852597 | Androgen associated hepatocellular carcinoma with an aggressive course. |
Q42982556 | Anti-HCV antibodies and hepatocellular carcinoma. Relationship in a medium-risk population |
Q43048217 | Anti-c100 antibodies to hepatitis C virus in patients with chronic hepatitis C virus infection treated with interferon |
Q43753998 | Antibodies to hepatitis C virus in patients undergoing hemodialysis in Salvador, BA, Brazil |
Q37534731 | Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection |
Q42981246 | Anti‐HCV antibody in Chinese cirrhotic patients with or without hepatocellular carcinoma: Relation to multitransfusion |
Q33617717 | Association between chronic hepatitis C infection and hepatocellular carcinoma in a Scottish population |
Q77908531 | B and C hepatitis viruses, HLA-DQ1 and -DR3 alleles and autoimmunity in patients with hepatocellular carcinoma |
Q38012691 | Cancer and viruses: a double-edged sword |
Q38466366 | Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study |
Q50849790 | Characteristics of hepatocellular carcinoma in Italy. |
Q27486074 | Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses |
Q42981306 | Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells |
Q27486027 | Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites |
Q42980768 | Characterization of the nuclear localization signal and subcellular distribution of hepatitis C virus nonstructural protein NS5A. |
Q30431528 | Chronic hepatitis C: the virus, its discovery and the natural history of the disease |
Q35236549 | Clinical aspects and epidemiology of hepatitis B and C viruses in hepatocellular carcinoma in Japan |
Q42980763 | Clinical evaluation of a newly established anti‐HCV assay for the diagnosis of hepatitis C in Japan |
Q27477946 | Clinical guidelines on the management of hepatitis C |
Q58033435 | Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma |
Q35233963 | Clinical spectrum of viral infections in hemophilic patients |
Q45392678 | Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma |
Q42991523 | Comparison of serum and liver hepatitis C virus quasispecies in HCV-related hepatocellular carcinoma |
Q45730394 | Correlation of clinical characteristics with detection of hepatitis B virus X gene in liver tissue in HBsAg-negative, and HCV-negative hepatocellular carcinoma patients |
Q45852327 | Correlation of hepatitis C virus antibodies with HIV-1 seropositivity in intravenous drug addicts |
Q45361548 | Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study. |
Q36496830 | Delayed development of hepatocellular carcinoma during long-term follow-up after eradication of hepatitis C virus by interferon therapy |
Q43040424 | Demonstration of HCV-RNA and HBV-DNA in the serum of HBsAg negative patients with hepatocellular carcinoma |
Q43038220 | Detection and analysis of replicating hepatitis C virus RNA in hepatocellular carcinoma tissues |
Q43048952 | Detection of hepatitis C infection by polymerase chain reaction among hemodialysis patients |
Q27485151 | Detection of hepatitis C virus (HCV) proteins by immunofluorescence and HCV RNA genomic sequences by non-isotopic in situ hybridization in bone marrow and peripheral blood mononuclear cells of chronically HCV-infected patients |
Q27488101 | Detection of hepatitis C virus sequences in sera with controversial serology by nested polymerase chain reaction |
Q27478449 | Detection of replicative hepatitis C virus sequences in hepatocellular carcinoma |
Q43048410 | Development of a specific enzyme-linked immunosorbent assay for the hepatitis C virus antibody using clone 14. |
Q42981934 | Development of antibody to hepatitis C virus (HCV) in acute and chronic non-A, non-B post-transfusion hepatitis |
Q50579359 | Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Is it possible to reduce the incidence by ribanirin and IFN combination therapy? |
Q67486488 | Development of hepatocellular carcinoma in a man with auto‐immune chronic active hepatitis |
Q45363707 | Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy. |
Q56561242 | Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma |
Q79823799 | Different presentation of hepatitis B-related hepatocellular carcinoma in a cohort of 1863 young and old patients - implications for screening |
Q51090924 | Dilemma of the natural history of hepatitis C. |
Q24653498 | Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin-beta receptor modulates the signal pathway of the lymphotoxin-beta receptor |
Q33407730 | Discovery of the hepatitis C virus |
Q27488868 | Discrimination of hepatitis C virus in liver tissues from different patients with hepatocellular carcinomas by direct nucleotide sequencing of amplified cDNA of the viral genome |
Q40850644 | Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients |
Q34683615 | Does hepatitis C virus cause severe liver disease only in people who drink alcohol? |
Q44012761 | Does hepatitis C virus infection contribute to hepatocellular carcinoma in hong kong? |
Q52909973 | Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. |
Q43450451 | Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. |
Q55094662 | Effects of continuous hepatitis with persistent hepatitis C viremia on outcome after resection of hepatocellular carcinoma. |
Q33972219 | Effects of storage and type of blood collection tubes on hepatitis C virus level in whole blood samples |
Q45367944 | Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus. |
Q45783851 | Efficacy of an analysis of lymphocyte subsets in predicting the clinical response to alpha-interferon therapy in thalassaemia patients with chronic infection by hepatitis C virus: a pilot study |
Q43031055 | Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone |
Q27473016 | Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA |
Q73451716 | Efficacy of prophylactic sclerotherapy in patients with hepatocellular carcinoma and varices negative for the red color sign |
Q28484539 | Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats |
Q37906017 | Epidemiology of chronic viral hepatitis in the Mediterranean area: present status and trends |
Q36447914 | Epidemiology of hepatitis C virus in Japan: role in chronic liver disease and hepatocellular carcinoma |
Q70756324 | Epidemiology of hepatitis C virus infection |
Q45704455 | Evaluation of loss of heterozygosity before and after interferon therapy in patients with hepatitis C virus infection who developed hepatocellular carcinoma during follow up. |
Q27469317 | Evidence for hepatitis C viral infection in patients with primary hepatocellular carcinoma |
Q73549886 | Excess mortality from hepatocellular carcinoma in an HCV-endemic township of an HBV-endemic country (Taiwan) |
Q27486022 | Expression and identification of hepatitis C virus polyprotein cleavage products |
Q58862457 | Expression of thec-myc protooncogene product in cells infected with the hepatitis delta virus |
Q24563988 | Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma |
Q72855674 | Follow-up study of acute hepatitis C |
Q42988155 | Frequent detection of hepatitis C virus US strain in Japanese hemophiliacs |
Q44236813 | GSTT1 null genotype contributes to hepatocellular carcinoma risk: a meta-analysis |
Q43048277 | Genotypic subtyping of hepatitis C virus |
Q37903326 | Geographic heterogeneity of hepatocellular carcinoma. |
Q39381895 | Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology). |
Q40172999 | Glycyrrhizin injection therapy prevents hepatocellular carcinogenesis in patients with interferon-resistant active chronic hepatitis C. |
Q41818102 | HBV & HCV - awareness in acute abdomen emergency cases |
Q42981930 | HCV RNA and antibody to HCV core protein in Japanese patients with chronic liver disease |
Q72048519 | HCV infection and hepatocellular carcinoma in cirrhotics: what is the linkage? |
Q43039277 | HCV infection in alcoholics. |
Q42982244 | HCV infection in symptom-free patients |
Q42985994 | HCV infection, hepatic HLA display and composition of the mononuclear cell inflammatory infiltrate in chronic alcoholic liver disease |
Q42996927 | HCV seroreactivity and detection of HCV RNA in cirrhotics |
Q42978297 | HCV-associated hepatocellular carcinoma without cirrhosis |
Q40818830 | HVR1 quasispecies analysis from a long-term culture of hepatitis C virus in Hep G2 derived cells grown in a haemodialysis cartridge |
Q42983276 | Hepatitis B and C viral infections in patients with hepatocellular carcinoma |
Q43038729 | Hepatitis B virus DNA in serum and liver is commonly found in chinese patients with chronic liver disease despite the presence of antibodies to HBsAg |
Q35231554 | Hepatitis B virus infection and primary hepatocellular carcinoma |
Q42980930 | Hepatitis B virus markers and antibodies to hepatitis C virus in Japanese patients with hepatocellular carcinoma |
Q33929132 | Hepatitis B, C & D viral markers in multitransfused thalassemic children: long-term complications and present management |
Q42978560 | Hepatitis C biochemical remission and viral replication in haemodialysis patients |
Q55241882 | Hepatitis C in deceased drug addicts. |
Q43047908 | Hepatitis C infection in children and adolescents on haemodialysis and after renal transplant |
Q42984610 | Hepatitis C infection in renal transplant recipients in Israel |
Q35960912 | Hepatitis C infection in transplantation |
Q43037190 | Hepatitis C virus (HCV) RNA level determined by second-generation branched-DNA probe assay as predictor of response to interferon treatment in patients with chronic HCV viremia |
Q77720263 | Hepatitis C virus NS3/4A protease |
Q42986534 | Hepatitis C virus RNA genome in plasma of patients with non-A, non-B hepatitis |
Q43036983 | Hepatitis C virus RNA in serum and liver histology in asymptomatic anti-HCV positive subjects. |
Q36135489 | Hepatitis C virus RNA in southern African blacks with hepatocellular carcinoma |
Q28283484 | Hepatitis C virus and hepatocarcinogenesis |
Q73235881 | Hepatitis C virus and hepatocellular carcinoma |
Q45858814 | Hepatitis C virus and hepatocellular carcinoma in France: detection of antibodies using two second generation assays |
Q35891695 | Hepatitis C virus and lichen planus |
Q37887627 | Hepatitis C virus and transfusion transmitted liver disease: review |
Q39243681 | Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma |
Q43036518 | Hepatitis C virus antibody and hepatitis C virus replication in chronic hepatitis B patients |
Q43048361 | Hepatitis C virus associated primary hepatocellular carcinoma in a noncirrhotic liver |
Q27480393 | Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype |
Q42983445 | Hepatitis C virus detection is facilitated by the combined use of c100 protein and GOR epitope. |
Q37362701 | Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis |
Q27490250 | Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience |
Q42980514 | Hepatitis C virus genotypes in patients with hepatocellular carcinoma and cholangiocarcinoma in Thailand |
Q43047220 | Hepatitis C virus in alcoholic patients with and without clinically apparent liver disease |
Q47555610 | Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature |
Q34144211 | Hepatitis C virus infection and risk of cancer: a population-based cohort study |
Q26829202 | Hepatitis C virus infection and type 1 and type 2 diabetes mellitus |
Q43863350 | Hepatitis C virus infection in African patients with liver cirrhosis or primary hepatocellular carcinoma |
Q45775194 | Hepatitis C virus infection in Greece and its role in chronic liver disease and hepatocellular carcinoma |
Q42981412 | Hepatitis C virus infection in chronic liver disease and hepatocellular carcinoma in Saudi Arabia |
Q41398433 | Hepatitis C virus infection in dialysis and renal transplantation |
Q42984545 | Hepatitis C virus infection in the development of hepatocellular carcinoma in cirrhosis |
Q44114739 | Hepatitis C virus infection is an additive risk factor for development of hepatocellular carcinoma in patients with cirrhosis |
Q45875781 | Hepatitis C virus infection, HBsAg carrier state and hepatocellular carcinoma: relative risk and population attributable risk from a case-control study in Italy. |
Q41225114 | Hepatitis C virus infection: clinical aspects and treatment with interferon alfa |
Q39655346 | Hepatitis C virus replication in hepatocellular carcinoma |
Q27469295 | Hepatitis C virus. A review |
Q68477913 | Hepatitis C-associated hepatocellular carcinoma |
Q40404044 | Hepatitis C-related chronic liver disease among asymptomatic blood donors in the north west of England |
Q33339419 | Hepatitis C-virus (HCV) antibodies in patients after kidney transplantation |
Q71702111 | Hepatitis C: diagnosis and treatment |
Q42987946 | Hepatitis C: from laboratory to bedside |
Q35233238 | Hepatitis C: virology, epidemiology, clinical course, and treatment |
Q42042952 | Hepatitis type C virus infection in patients with type B chronic liver disease |
Q34528514 | Hepatocellular carcinoma and hepatitis C in the United States |
Q36401904 | Hepatocellular carcinoma. A worldwide problem and the major risk factors |
Q27489394 | Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis |
Q35227361 | Hepatocellular carcinoma: Recent progress |
Q27486176 | Hepatology |
Q43035375 | High level of hepatitis C endemicity in Gabon, equatorial Africa |
Q43039375 | High prevalence of hepatitis B and C viral markers in Japanese patients with hepatocellular carcinoma |
Q45881200 | High prevalence of hepatitis C virus infection in aborigines in Taiwan |
Q43037723 | High proportion of false positive reactions among donors with anti‐HCV antibodies in a low prevalence area |
Q35939195 | Histologic Study of Chronic Active Hepatitis C: Comparison with Chronic Active Hepatitis B |
Q26767036 | Historical review of the causes of cancer |
Q43576596 | Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion. |
Q34614394 | Human tumor-associated viruses and new insights into the molecular mechanisms of cancer |
Q42982497 | Identification of hepatitis B virus integration in hepatitis C virus-infected hepatocellular carcinoma tissues |
Q27480600 | IgG1 anti-P2 as a marker of response to interferon in patients with chronic hepatitis C |
Q45789715 | Impact of screening blood donors for hepatitis C antibody on posttransfusion hepatitis: a prospective study with a second‐generation anti‐hepatitis C virus assay |
Q42989419 | In situ detection of hepatitis B, C, and G virus nucleic acids in human hepatocellular carcinoma tissues from different geographic regions |
Q33906429 | Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis |
Q41141514 | Induction of apoptosis in a human hepatocellular carcinoma cell line by a neutralizing antibody to transforming growth factor-alpha |
Q35489328 | Infection and cancer: current state of art |
Q34538006 | Interaction between alcohol consumption and positivity for antibodies to hepatitis C virus on the risk of liver cirrhosis: a case-control study. Provincial Group for the Study of Chronic Liver Disease |
Q40937852 | Interactions between alcohol and hepatitis viruses in the liver. |
Q60211106 | Interferon for chronic hepatitis C in patients cured of malignancy |
Q42987918 | Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus |
Q42984591 | Intrafamilial transmission of hepatitis C. |
Q44181005 | Irregularity of parenchymal echo patterns of liver analyzed with a neural network and risk of hepatocellular carcinoma in liver cirrhosis |
Q24648164 | Kinetic and structural analyses of hepatitis C virus polyprotein processing |
Q42980799 | Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis |
Q43409999 | Liver cancer and non-Hodgkin lymphoma in hepatitis C virus-infected patients: results from the DANVIR cohort study |
Q72421238 | Liver disease |
Q43753027 | Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. |
Q45737371 | Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study |
Q43595642 | Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group |
Q45858833 | Long-term persistence of hepatitis C virus antibodies in a single source outbreak |
Q74530378 | Loss of butyrate-induced apoptosis in human hepatoma cell lines HCC-M and HCC-T having substantial Bcl-2 expression |
Q45858875 | Low prevalence of hepatitis C virus and infrequent perinatal or spouse infections in pregnant women in Taiwan |
Q43035439 | Low-dose interferon in chronic hepatitis non-A/non-B: effects on quantitative liver function and structure in a randomized, controlled multicenter trial |
Q34798261 | Lymphoblastoid interferon alfa treatment in chronic hepatitis C |
Q45886289 | Management of chronic hepatitis C. |
Q27477721 | Managing chronic hepatitis C virus infection |
Q35092460 | Mechanisms of alcohol-induced tissue injury |
Q30468280 | Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today? |
Q35832747 | Modulation of the trans-suppression activity of hepatitis C virus core protein by phosphorylation |
Q36469423 | Molecuar biology of hepatocellular carcinoma and hepatitis B virus association |
Q36441749 | Molecular biology of non-A, non-B hepatitis agents: hepatitis C and hepatitis E viruses |
Q27860811 | Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis |
Q37858630 | Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection |
Q42998892 | Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality |
Q43035596 | Mooren-type hepatitis C virus-associated corneal ulceration. |
Q45767597 | Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis |
Q33809420 | Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma |
Q26749329 | New advances in hepatocellular carcinoma |
Q42105512 | New antiviral agents for hepatitis C |
Q27469293 | Non-A, non-B hepatitis |
Q45857078 | Non-parenteral transmission of hepatitis C virus |
Q44444276 | Occupational risk for hepatitis C virus infection among New York City dentists |
Q53579868 | Outcome of small (10-20 mm) arterial phase-enhancing nodules seen on triphasic liver CT in patients with cirrhosis or chronic liver disease. |
Q42050840 | Oval cell numbers in human chronic liver diseases are directly related to disease severity. |
Q52139868 | Parenchymal echo patterns of cirrhotic liver analysed with a neural network for risk of hepatocellular carcinoma. |
Q41332812 | Patterns of progression: unpredictability and risk of decompensated cirrhosis |
Q62658386 | Persistence of Hepatitis B and Hepatitis C Viral Genomes in Primary Liver Cancers from HBsAg-Negative Patients: A Study of a Low-endemic Area |
Q33818746 | Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial |
Q45749872 | Possible contribution to hepatocarcinogenesis of X transcript of hepatitis B virus in Japanese patients with hepatitis C virus |
Q43749890 | Practical approach to the discovery of a positive HCV serology in a blood donor |
Q44511056 | Presence of anti-hepatitis C virus serum markers in a dental school patient population |
Q43671045 | Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL. |
Q42986046 | Prevalence and significance of antibodies to hepatitis c virus among Saudi haemodialysis patients |
Q35939128 | Prevalence of Antibodies to Hepatitis C Virus in Patients with Various Types of Liver Diseases |
Q42988143 | Prevalence of anti-HCV antibodies in patients with chronic liver disease and its relationship to HBV and HDV infections |
Q42980969 | Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis |
Q43035800 | Prevalence of antibodies to hepatitis C virus in Greek patients with chronic liver disease |
Q45789661 | Prevalence of antibodies to hepatitis C virus in Greek patients with chronic liver disease |
Q45871217 | Prevalence of antibodies to hepatitis C virus in patients with hepatocellular carcinoma in Austria |
Q45850898 | Prevalence of antibody against non-A, non-B hepatitis virus in Japanese patients with hepatocellular carcinoma |
Q42985722 | Prevalence of antibody against the core protein of hepatitis C virus in patients with hepatocellular carcinoma |
Q43034959 | Prevalence of hepatitis C antibody in patients with chronic liver disease and hepatocellular carcinoma in Korea |
Q42981825 | Prevalence of hepatitis C virus antibodies in chronic liver disease and hepatocellular carcinoma patients in India |
Q27485927 | Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini |
Q62607309 | Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis |
Q34508847 | Prospective study on the relation of cigarette smoking with cancer of the liver and stomach in an endemic region |
Q27487881 | Quantitation of hepatitis C virus genome molecules in plasma samples |
Q53460454 | Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. |
Q43048173 | Relation of hepatitis C virus to hepatocellular carcinoma |
Q45764849 | Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. |
Q43039289 | Relevance of anti-HCV reactivity in patients with alcoholic hepatitis. VA cooperative Study Group #275. |
Q77221798 | Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis |
Q36684658 | Review of hepatitis C in Japan |
Q43049218 | Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon |
Q42980410 | Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study |
Q51872438 | Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres. |
Q72082159 | Risk Factors for Hepatocellular Carcinoma among Patients with Chronic Liver Disease |
Q26775650 | Risk Factors for the Development of Hepatocellular Carcinoma in Thailand |
Q50619400 | Risk factors and prevention of hepatocellular carcinoma in HCV infection. |
Q43330713 | Risk factors in community-acquired chronic hepatitis C virus infection: a case-control study in Italy |
Q57763153 | Risk of Hepatocellular Carcinoma Development in Cases of Hepatitis C Treated by Long-Term, Low-Dose PEG-IFNa-2a |
Q79294727 | Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma |
Q42981016 | Role of hepatitis C virus in acute non-A, non-B hepatitis in Greece: A 5-Year prospective study |
Q55130799 | Role of increased DNA synthesis activity of hepatocytes in multicentric hepatocarcinogenesis in residual liver of hepatectomized cirrhotic patients with hepatocellular carcinoma. |
Q74027220 | Screening for hepatocellular carcinoma |
Q84921251 | Screening for hepatocellular carcinoma |
Q71684510 | Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein |
Q43048384 | Serodiagnosis of chronic hepatitis C in Japan by second-generation recombinant immunoblot assay |
Q37519291 | Serodiagnosis of hepatitis C virus (HCV) infection with an HCV core protein molecularly expressed by a recombinant baculovirus |
Q42983311 | Seropositivity to hepatitis C virus (HCV) in Saudi children with chronic renal failure maintained on haemodialysis |
Q79299908 | Seroprevalence and outcome of hepatitis C in liver transplantation |
Q44684456 | Serum alanine aminotransferase levels and survival after hepatectomy in patients with hepatocellular carcinoma and hepatitis C virus-associated liver cirrhosis |
Q50565830 | Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C. |
Q33640766 | Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4 |
Q27477689 | Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV |
Q44488142 | Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy. Result of multivariate analysis |
Q41302293 | Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides |
Q46514306 | Strenuous physical labor is important as a cause of elevated alanine aminotransferase levels in Japanese patients with chronic hepatitis C viremia |
Q27478443 | Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase |
Q27486067 | Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells |
Q67486992 | Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis |
Q34609714 | Survival rates of early-stage HCV-related liver cirrhosis patients without hepatocellular carcinoma are decreased by alcohol |
Q43000578 | Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma |
Q42984313 | Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. |
Q58802894 | T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections |
Q64069871 | The association of liver function and quality of life of patients with liver cancer |
Q36409001 | The detection of hepatitis B virus (HBV) in HBsAG negative individuals with primary liver cancer |
Q54759655 | The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma. |
Q37576273 | The hepatitis C virus and its relationship to the clinical spectrum of NANB hepatitis |
Q24610004 | The history of tumor virology |
Q72085589 | The male preponderance in incidence of hepatocellular carcinoma in cirrhotic patients may depend on the higher DNA synthetic activity of cirrhotic tissue in men |
Q41098848 | The molecular pathogenesis of hepatocellular carcinoma. |
Q35960890 | The natural history of chronic hepatitis C virus infection |
Q35035439 | The natural history of hepatocellular carcinoma. |
Q39418450 | The oncologic burden of hepatitis C virus infection: A clinical perspective. |
Q45853309 | The polymerase chain reaction for hepatitis B virus DNA. |
Q45178683 | The prevalence of anti-hepatitis C virus among chinese patients with hepatocellular carcinoma |
Q33394200 | The prevalence of antibody to hepatitis C virus (anti-HCV) in patients with acute and chronic liver diseases in Jakarta, Indonesia |
Q45854272 | The prevalence of hepatitis C virus antibody in high risk group of Thai children and adults |
Q42981043 | The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study |
Q43039226 | The role of hepatitis C virus in chronic hepatitis B virus infection |
Q45786134 | The sexual transmission of hepatitis C virus |
Q42988133 | The significance of anti-hepatitis C virus antibodies measured in chronic liver disease |
Q35747461 | Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin |
Q42988100 | Transition of antibody to hepatitis C virus from chronic hepatitis to hepatocellular carcinoma |
Q57951603 | Tropical medicine |
Q44454738 | Type C viral hepatitis |
Q35581216 | Ultrastructural alterations and expression of cytoplasmic antigen 48-1 in hepatocytes in association with hepatitis C virus infection |
Q43036129 | Use of confirmatory assays for diagnosis of hepatitis C viral infection in patients with hepatocellular carcinoma |
Q33894872 | View and review on viral oncology research |
Q68008537 | Viral hepatitis |
Q21245597 | Viral hepatitis and hepatocellular carcinoma |
Q72749710 | [Hepatitis C] |
Search more.